Michael Yee
Stock Analyst at Jefferies
(2.72)
# 2,020
Out of 4,924 analysts
82
Total ratings
40%
Success rate
7.63%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRGX CARGO Therapeutics | Maintains: Hold | $3.7 → $5 | $4.47 | +11.86% | 4 | Jul 8, 2025 | |
| ALXO ALX Oncology Holdings | Upgrades: Buy | $2 → $3 | $0.69 | +337.25% | 5 | Mar 6, 2025 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $8.13 | +146.00% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $129.50 | +39.00% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $385.00 | +42.86% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $284.84 | +33.41% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $14.30 | +214.69% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $26.51 | +107.51% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $11.58 | +202.38% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $14.06 | +184.50% | 1 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $863.95 | -55.44% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $2.33 | +330.11% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $3.50 | -14.29% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $18.52 | +61.99% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $15.04 | +32.98% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $34.63 | -42.25% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $8.06 | +830.52% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $2.52 | +1,090.48% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $32.04 | +102.87% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,875 → $1,125 | $7.10 | +15,745.07% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $1.90 | +1,483.11% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $7.91 | +279.27% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $18.77 | +539.32% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $19.27 | +289.21% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $20.95 | +43.20% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $19.56 | +293.66% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $110.57 | - | 3 | Jan 26, 2018 |
CARGO Therapeutics
Jul 8, 2025
Maintains: Hold
Price Target: $3.7 → $5
Current: $4.47
Upside: +11.86%
ALX Oncology Holdings
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $0.69
Upside: +337.25%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $8.13
Upside: +146.00%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $129.50
Upside: +39.00%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $385.00
Upside: +42.86%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $284.84
Upside: +33.41%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $14.30
Upside: +214.69%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $26.51
Upside: +107.51%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $11.58
Upside: +202.38%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $14.06
Upside: +184.50%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $863.95
Upside: -55.44%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.33
Upside: +330.11%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $3.50
Upside: -14.29%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $18.52
Upside: +61.99%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $15.04
Upside: +32.98%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $34.63
Upside: -42.25%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $8.06
Upside: +830.52%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $2.52
Upside: +1,090.48%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $32.04
Upside: +102.87%
Mar 2, 2021
Downgrades: Hold
Price Target: $1,875 → $1,125
Current: $7.10
Upside: +15,745.07%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $1.90
Upside: +1,483.11%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $7.91
Upside: +279.27%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $18.77
Upside: +539.32%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $19.27
Upside: +289.21%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $20.95
Upside: +43.20%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $19.56
Upside: +293.66%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $110.57
Upside: -